Tacrolimus Levels in the Prophylaxis of Acute Graft-Versus-Host Disease in the Chinese Early After Hematopoietic Stem Cell Transplantation.

摘要: Background Tacrolimus has been widely accepted as the backbone of acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (alloHSCT). The present work evaluated whether tacrolimus concentrations early after transplant correlate with incidence aGVHD Chinese alloHSCT recipients. Methods One hundred four recipients were included this retrospective study. All patients received standard and short-term methotrexate. Blood samples taken at steady-state for those on i.v. (Cv) or predose (C0) 2 hours last oral dose (C2). Results In first 8 weeks alloHSCT, significant variability Cv, C0, C2 was observed. It found that higher C0 values tended to be associated a reduced risk aGVHD, although nonsignificant trend due small sample size involved. Receiver operating characteristic curve analysis indicated Cv levels ≥16.52 ng/mL, ≥5.56 ≥7.83 ng/mL minimized treatment failure during 3-4 intravenous administration 5-6 administration. There no statistically association patient liver kidney function blood concentration desired range 5-20 ng/mL. Conclusions therapeutic drug monitoring improved outcomes measurements better predicted (I-IV) than measured other time points 6 alloHSCT.